Your search found 3 Results
Global AIDSLink. 2003 Jun-Jul; 12.A bill was drafted and finally endorsed in early 1998 stating that the vaccine candidate had a favorable safety profile from pre-clinical and clinical testing in the country of origin; that there was evidence of clear benefit to the population; that there was a Memorandum of Understanding affirming interaction between UNAIDS/WHO manufacturers/sponsoring agencies and Ugandan representatives; and that the final decision about the vaccine candidate would be made by the government of Uganda, and endorsed by the parliament. The media closely followed these processes and, in February 1998, 40 army men -- a cohort that had undergone intensive preparation for 18 months since 1994 -- became the first volunteers recruited for the study. Despite the protracted nature of the process, it paved the way for other vaccine candidates to enter Uganda with minimal resistance, in an environment with the necessary infrastructure and level of community preparedness. Uganda now has an HIV Vaccine Preparedness Plan and, while the ALVAC trial ended successfully in 2001, three other vaccine candidates have already found their way into the country. (excerpt)
Journal of the Association of Nurses in AIDS Care. 1999; 10(1):17-20.There is a need for increasing international collaboration in the search for a safe and effective HIV vaccine. In addition to the ethical issues that must be considered in conducting any clinical research, unique issues arise in vaccine research and in international research. Careful deliberation and guideline development regarding the ethics of international vaccine research was the focus of a series of recent consultations sponsored by Joint United Nations Programme on HIV/AIDS (UNAIDS) around the world. (author's)
Lancet. 1999 Sep 11; 354(9182):923.This article reports on the completion of the UNAIDS document on ethical considerations in HIV-vaccine research, which is the second major attempt to draft universally acceptable ethical guidelines. The document includes 18 guidance points, followed by annotations. The guidance point stipulates that communities involved, as a trial must be a party to the research protocol. The document also presented some difficult guidance points to negotiate. To mention a few, one guidance point requires a pretrial agreement of care packages for research participants who acquire HIV infection during a vaccine trial. Another controversial guidance point is that any vaccine shown to be safe and effective should be made available to all participants and eventually to the whole population.